Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03194867
Recruitment Status : Active, not recruiting
First Posted : June 21, 2017
Last Update Posted : July 15, 2019
Sponsor:
Information provided by (Responsible Party):
Sanofi

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2020
  Estimated Study Completion Date : April 2020